Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20474454 | 1.00 | CAPN1 (0.58) | CAPN1MMELTA4HMMP2MMP7 | |
| SCHEMBL20474455 | 1.00 | CAPN1 (0.58) | CAPN1MMELTA4HMMP2MMP7 | |
| SCHEMBL20815801 | 0.92 | CAPN1 (0.53) | CAPN1MME | |
| SCHEMBL20815800 | 0.92 | CAPN1 (0.53) | CAPN1MME | |
| SCHEMBL20873441 | 0.91 | CAPN1 (0.56) | CAPN1MME | |
| SCHEMBL20873442 | 0.91 | CAPN1 (0.56) | CAPN1MME | |
| SCHEMBL17595916 | 0.90 | CTSL (0.61) | CAPN1MME | |
| SCHEMBL20474469 | 0.90 | CTSL (0.61) | CAPN1MME | |
| SCHEMBL21458073 | 0.88 | ANPEP (0.50) | MMEMMP2MMP12MMP13 | |
| SCHEMBL3837984 | 0.88 | ANPEP (0.50) | MMEMMP2MMP12MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160190448-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| EP-1692098-B1 | ALPHA-KETOAMIDE DERIVATIVE, AND PRODUCTION METHOD AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, ERH | CAPN1 2767/4885MME 3709/4885LTA4H 779/4885 |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | CAPN1 4158/4885MME 3276/4885LTA4H 2510/4885 |
| US-20160190448-A1 | CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CCNT1, CCNE2, CRY1 | CAPN1 3539/4885MME 4190/4885LTA4H 951/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885MME 2370/4885LTA4H 1933/4885 |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | CAPN1 2695/4885MME 3668/4885LTA4H 773/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | CAPN1 4158/4885MME 3276/4885LTA4H 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.